A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors

SGLT2 inhibitors may have a potential to stop the decline of renal function independent of the stage of albuminuria in diabetic kidney disease, and can be a new light in the post‐RAS inhibitor era.[Image: see text]

Detalles Bibliográficos
Autores principales: Kume, Shinji, Maegawa, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077719/
https://www.ncbi.nlm.nih.gov/pubmed/35029051
http://dx.doi.org/10.1111/jdi.13747
_version_ 1784702172310536192
author Kume, Shinji
Maegawa, Hiroshi
author_facet Kume, Shinji
Maegawa, Hiroshi
author_sort Kume, Shinji
collection PubMed
description SGLT2 inhibitors may have a potential to stop the decline of renal function independent of the stage of albuminuria in diabetic kidney disease, and can be a new light in the post‐RAS inhibitor era.[Image: see text]
format Online
Article
Text
id pubmed-9077719
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90777192022-05-13 A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors Kume, Shinji Maegawa, Hiroshi J Diabetes Investig Update SGLT2 inhibitors may have a potential to stop the decline of renal function independent of the stage of albuminuria in diabetic kidney disease, and can be a new light in the post‐RAS inhibitor era.[Image: see text] John Wiley and Sons Inc. 2022-02-03 2022-05 /pmc/articles/PMC9077719/ /pubmed/35029051 http://dx.doi.org/10.1111/jdi.13747 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Update
Kume, Shinji
Maegawa, Hiroshi
A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
title A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
title_full A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
title_fullStr A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
title_full_unstemmed A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
title_short A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
title_sort new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
topic Update
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077719/
https://www.ncbi.nlm.nih.gov/pubmed/35029051
http://dx.doi.org/10.1111/jdi.13747
work_keys_str_mv AT kumeshinji aneweraofdiabetickidneydiseasetreatmentwithsodiumglucosecotransporter2inhibitors
AT maegawahiroshi aneweraofdiabetickidneydiseasetreatmentwithsodiumglucosecotransporter2inhibitors
AT kumeshinji neweraofdiabetickidneydiseasetreatmentwithsodiumglucosecotransporter2inhibitors
AT maegawahiroshi neweraofdiabetickidneydiseasetreatmentwithsodiumglucosecotransporter2inhibitors

Ejemplares similares